HCA launches media relations best practice guide
June 5, 2007Medical Communications
The Healthcare Communications Association has unveiled a new guide to working with the media, the first in a series of …
Product roundup from Datamonitor
June 4, 2007Sales and Marketing
Celsion completes enrolment in phase I liver cancer studyCelsion has completed its phase I dose escalation study, using ThermoDox, to …
Clew to promote Novartis’ Aclasta
May 31, 2007Medical Communications
Novartis has appointed Clew Communications to run a pre-launch and launch PR campaign for its new osteoporosis drug.Aclasta (zoledronic acid) …
NICE approves Pfizer’s Champix
May 31, 2007Pfizer's first-in-class smoking cessation drug Champix has received approval from NICE one month before England's smoking ban comes into effect.Champix …
China’s former medicines regulator sentenced to death
May 31, 2007Sales and Marketing
The former head of China's medicines regulator has been sentenced to death after being found guilty of taking bribes to …
Genzyme buys cancer specialists Bioenvision
May 31, 2007Research and Development
Genzyme is to spend $345 million on acquiring specialist pharma company Bioenvision and its oncology portfolio.Genzyme already co-markets with Bioenvision …
Avandia safety concerns hit GSK shares
May 31, 2007Sales and Marketing
Shares in GSK have taken another hit after news that US prescribers have turned away from diabetes drug Avandia in …
Product roundup from Datamonitor
May 29, 2007Sales and Marketing
ADHD drug as effective in boys as girls, says ShireUK pharmaceutical company Shire has said that results from a study …
Industry outlines concerns with NICE to Parliament
May 24, 2007NICE's shortfalls have compromised public confidence in the cost and clinical-effectiveness body, the pharmaceutical industry has told MPs.The comments were …
PCTs ‘overspending’ on prescribing
May 24, 2007PCTs could save the NHS more than £200 million if they can persuade more GPs to prescribe generically, according to …
Report raises safety concerns over Avandia
May 24, 2007Sales and Marketing
GlaxoSmithKline has been forced on the defensive after its blockbuster diabetes treatment Avandia was linked to an increased risk of …
The Changing Face of Medical Education
May 23, 2007Medical Communications, Sales and Marketing medical education
Is Medical Education the new PR?Phil Sheldon, Managing Director, Resolute Communications:Clients are increasingly waking up to the fact that medical …
Charity outlines vision for tackling cancer
May 23, 2007Sales and Marketing
Cancer Research UK has set out an ambitious list of goals to reach by 2020, which it hopes will inspire …
Pfizer loses heads of research and finance
May 23, 2007Research and Development, Sales and Marketing
Two key Pfizer executives are to step down as the company continues its drive to reinvigorate itself.The departures follow the …
Edelman scoops European Viagra account
May 23, 2007Medical Communications
Pfizer has appointed PR agency Edelman to raise the European profile of its blockbuster erectile dysfunction treatment, Viagra.The company has …
Latest news from Datamonitor
May 23, 2007Sales and Marketing
Breast cancer patients may be offered chemo-free treatmentHormone therapy drugs such as AstraZeneca's Zoladex may be as effective as traditional …
Med Ed comes of age
May 17, 2007Medical Communications, Sales and Marketing medical education
Even a casual observer will have noticed the large contribution pharma makes to postgraduate medical education, both in the UK …
Roche selects Ketchum for pandemic work
May 17, 2007Medical Communications
PR agency Ketchum has scooped a global account for Tamiflu as Roche begins further research into its use against bird …
Clinical news from Datamonitor
May 17, 2007Research and Development
FDA requests additional efficacy data for Dendreon's Provenge in advanced prostate cancer.Dendreon has received a complete response letter from the …
Pharma news from Datamonitor
May 17, 2007Sales and Marketing
Meda and Ethypharm collaborate on NSAIDMeda and Ethypharm have signed an exclusive 15-year agreement for an innovative NSAID product which …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
